Emerging Role of Finerenone in The Management of Hypertension: A New Frontier in The Minrelocorticoid Receptor Antagonism

Prevalence of Hypertension

Hypertension, often termed the “silent killer,” is a prevalent and persistent public health burden affecting over one billion individuals globally (1). It is a primary etiological factor for cardiovascular complications such as myocardial infarction, stroke, and heart failure, as well as progressive renal impairment. The asymptomatic nature of the condition often results in delayed diagnosis and suboptimal management. Despite the availability of a wide spectrum of antihypertensive agents, global control rates remain unsatisfactory, especially in individuals with complex comorbidities. This underscores the urgent need for novel, targeted therapies that go beyond conventional blood pressure reduction and address underlying pathophysiological mechanisms (2).

The pathophysiology of hypertension is multifactorial, involving genetic, environmental, and behavioral factors. Lifestyle-related contributors such as obesity, high salt intake, sedentary habits, and stress exacerbate the prevalence, particularly in urban populations (3). In many cases, blood pressure remains poorly controlled despite the use of multiple antihypertensive agents, highlighting issues of therapeutic resistance, patient non-compliance, and limited access to effective care.

Furthermore, the coexistence of hypertension with conditions like diabetes and CKD complicates management, necessitating multidimensional treatment strategies. The inadequacy of current therapies to address the full spectrum of pathophysiological changes associated with hypertension has stimulated research into more targeted and disease-modifying interventions. This has paved the way for newer pharmacologic innovations such as finerenone, a novel mineralocorticoid receptor antagonist with promising benefits in hypertension management and organ protection.

Need for New Therapeutic Strategies

Although a broad range of antihypertensive agents—such as diuretics, ACE inhibitors, calcium channel blockers, and beta-blockers—are available, a significant subset of patients continues to exhibit inadequate blood pressure control. This is particularly evident in individuals with treatment-resistant hypertension, defined as blood pressure that remains elevated despite adherence to a regimen of three or more antihypertensive drugs, including a diuretic. In these cases, standard therapies may fail to target the deeper pathophysiological mechanisms driving vascular dysfunction and end-organ damage (4).

The complexity increases further when hypertension coexists with chronic kidney disease (CKD), type 2 diabetes mellitus, or heart failure. In such populations, inflammation, oxidative stress, and tissue fibrosis contribute not only to the persistence of elevated blood pressure but also to the progression of structural and functional damage in the kidneys, heart, and vasculature (5). Traditional antihypertensives primarily target hemodynamic regulation, often overlooking these non-pressure-related pathological processes.

Role of the Mineralocorticoid Receptor (MR)

The mineralocorticoid receptor (MR) is a nuclear receptor that plays a central role in regulating fluid and electrolyte balance, primarily through its action in the distal nephron of the kidney. Under normal physiological conditions, MR is activated by aldosterone, a hormone secreted by the adrenal cortex in response to stimuli such as low blood pressure or elevated potassium levels. This activation promotes sodium reabsorption and potassium excretion, leading to increased blood volume and, consequently, elevated blood pressure.

However, in pathological states such as chronic hypertension, heart failure, and chronic kidney disease, there is often inappropriate or excessive activation of the MR. This overstimulation extends beyond fluid balance and contributes to pro-inflammatory, pro-fibrotic, and pro-oxidative changes in cardiovascular and renal tissues. Sustained MR activation promotes vascular stiffness, myocardial fibrosis, glomerular injury, and endothelial dysfunction—all of which exacerbate hypertension and accelerate target organ damage (6) as shown in Figure 1.

The recognition of MR’s broader role in promoting tissue injury independent of hemodynamic changes has shifted therapeutic focus. Targeting MR with more selective and potent antagonists that can inhibit these non-classical pathways is now seen as a promising strategy. This evolving understanding sets the foundation for the therapeutic potential of finerenone (7). which offers greater specificity, minimal hormonal side effects, and additional anti-fibrotic and anti-inflammatory properties, positioning it as a next-generation agent in the management of hypertension and related complications.

Figure 1: Mechanistic Pathways Influenced by Mineralocorticoid Receptor  Activation. This flowchart illustrates the key biological effects of mineralocorticoid receptor (MR) activation. https://doi.org/10.3389/fendo.2023.1125693

Introduction to Finerenone

Finerenone is a next-generation, non-steroidal, and highly selective mineralocorticoid receptor antagonist (MRA) that has garnered considerable attention for its multifaceted role in the attenuation of cardio-renal pathology, particularly in patients with hypertension and associated comorbidities. It was rationally designed to surmount the pharmacokinetic and pharmacodynamic limitations of conventional steroidal MRAs such as spironolactone and eplerenone (8).

Pharmacologically, finerenone exhibits high-affinity binding to the mineralocorticoid receptor while preserving a remarkable degree of tissue selectivity and receptor specificity. Unlike its steroidal counterparts, which often exert off-target hormonal effects due to their interaction with androgen and progesterone receptors, finerenone avoids these adverse endocrine sequelae owing to its structural divergence and receptor selectivity.

One of the hallmark features of finerenone is its equilibrated biodistribution across cardiac and renal tissues, facilitating concerted anti-fibrotic and anti-inflammatory actions in both organs. These pleiotropic effects are critical, as pathological MR activation is implicated in the propagation of vascular remodeling, myocardial fibrosis, and glomerular sclerosis—all of which potentiate the progression of hypertension and target organ dysfunction.

Moreover, finerenone is associated with a significantly attenuated risk of hyperkalemia, a notorious complication of older MRAs, thereby improving its therapeutic tolerability in vulnerable populations such as patients with chronic kidney disease (CKD) or diabetes mellitus. Its favorable pharmacological index, combined with robust evidence from pivotal clinical trials (e.g., FIDELIO-DKD and FIGARO-DKD), underscores its emergent role as a paradigm-shifting agent in the comprehensive management of hypertension, particularly within the context of cardio-renal syndromes (9).

Figure 2: structure of Finerenone

Mechanism of Action of Finerenone

Finerenone is a next-generation, non-steroidal mineralocorticoid receptor antagonist (MRA) that selectively inhibits the mineralocorticoid receptor (MR), a ligand-activated transcription factor that plays a pivotal role in sodium homeostasis, inflammation, and tissue fibrosis. In normal physiology, aldosterone binds to MR, particularly in renal epithelial cells, promoting sodium reabsorption and potassium excretion. However, under pathological conditions such as hypertension, diabetes, and chronic kidney disease, aldosterone levels remain elevated, and MR becomes aberrantly activated, contributing to widespread organ damage (10).

What distinguishes finerenone mechanistically is its ability to antagonize MR activation in both epithelial and non-epithelial tissues, including vascular smooth muscle cells, cardiac fibroblasts, and renal mesangial cells. By competitively blocking aldosterone from binding to MR, finerenone prevents the receptor’s nuclear translocation and subsequent interaction with DNA response elements. This action

downregulates the expression of pathogenic genes involved in pro-inflammatory and pro-fibrotic signaling pathways, such as serum/glucocorticoid-regulated kinase 1 (SGK1) and transforming growth factor-beta (TGF-β).

Additionally, finerenone exhibits a distinct receptor binding profile due to its non-steroidal, bulky molecular structure, which induces a unique MR conformation. This modified receptor structure preferentially recruits corepressors over coactivators, enhancing gene suppression rather than gene activation. This results in a more targeted blockade of deleterious aldosterone signaling compared to older steroidal MRAs like spironolactone, which may exhibit partial agonistic activity in certain tissues and bind to sex hormone receptors, leading to undesirable hormonal side effects(11).

Another critical pharmacological advantage of finerenone lies in its balanced distribution between the heart and kidneys, allowing simultaneous cardiorenal protection. By attenuating oxidative stress, inhibiting NADPH oxidase activity, and reducing macrophage infiltration, finerenone prevents endothelial dysfunction and tissue remodeling. These mechanisms significantly reduce the progression of glomerulosclerosis, vascular stiffness, myocardial fibrosis, and proteinuria, which are key contributors to hypertension-related end-organ damage (12) as represented in Table 1.

Table 1 : representing the mechanism of action of Finerenone

Finerenone has shown significant cardiorenal benefits, as demonstrated in pivotal trials like FIDELIO-DKD and FIGARO-DKD (13). These studies highlighted its ability to reduce both the progression of chronic kidney disease (CKD) and the incidence of major adverse cardiovascular events in patients with type 2 diabetes mellitus and hypertension.

Unlike traditional steroidal MRAs, Finerenone exhibits a favorable safety profile, with a lower incidence of hyperkalemia and minimal hormonal side effects (14), thereby improving patient adherence and therapeutic tolerability. Its unique non-steroidal structure allows for selective MR antagonism without off-target effects.

Additionally, growing clinical evidence suggests that Finerenone may provide superior blood pressure control, particularly in resistant or high-risk hypertensive populations. Its multifaceted action on inflammation, fibrosis, and vascular stiffness enhances its utility beyond standard antihypertensive agents (15), reinforcing its role in comprehensive cardiovascular and renal risk reduction.

Advantages Over Traditional MRAs

Finerenone, a next-generation non-steroidal antagonist of the mineralocorticoid receptor, distinguishes itself from traditional agents such as spironolactone and eplerenone by offering a more refined therapeutic profile (16). One of the most clinically meaningful benefits is its reduced propensity to induce hyperkalemia, which enhances its safety profile, especially in cases with habitual order complaint or those on concurrent renin- angiotensin system blockers (17).

In discrepancy to traditional MRAs, Finerenone demonstrates minimum commerce with coitus hormone receptors, thereby circumventing undesirable endocrine goods similar as gynecomastia, incompetence, and menstrual irregularities (18). This absence ofanti-androgenic or progestogenic exertion significantly improves tolerability and case compliance.

likewise, Finerenone exhibits superior towel selectivity, particularly in the heart and feathers, where it exerts potentanti-inflammatory and antifibrotic goods. Its enhanced receptor- binding kinetics and unique molecular structure contribute to its efficacity in modulating crucial pathophysiological processes involved in hypertension and cardiorenal complaint, making it a significant advancement in the class of MRAs (19) as shown in Figure 2.

In addition to its improved safety and receptor selectivity, Finerenone’s pharmacodynamic properties confer a distinct clinical edge. Its balanced tissue distribution enables more targeted inhibition of mineralocorticoid receptor overactivation within the myocardium and renal parenchyma, without affecting other systemic pathways. This refined mechanism reduces the risk of off-target effects and enhances its anti-inflammatory and antifibrotic potential, which are crucial in the attenuation of cardiovascular remodeling and renal fibrosis. As a result, Finerenone not only manages hypertension effectively but also contributes meaningfully to the long-term preservation of organ function, particularly in patients with comorbid conditions such as diabetes mellitus and chronic kidney disease.

Figure 4: Comparision – Finerenone vs Traditional MRAs.

“As shown in Figure 4, finerenone demonstrates a significantly lower risk of hyperkalemia and endocrine side effects compared to traditional MRAs, while offering superior tissue selectivity and anti-inflammatory benefits” https://doi.org/10.3390/jcm11010117

2. REVIEW OF LITERATURE

1. 1. Overview of Existing Research

Finerenone has surfaced over the once decade as a novel,non-steroidal mineralocorticoid receptor antagonist( MRA), representing a significant advancement in the pharmacologic geography for the operation of hypertension, particularly in cases with comorbid habitual order complaint( CKD) and type 2 diabetes mellitus( T2DM). The scientific interest in finerenone stemmed from the limitations of traditional steroidal MRAs similar as spironolactone and eplerenone, which, despite proven efficacity, are frequently associated with adverse endocrine goods( e.g., gynecomastia, menstrual irregularities) and a heightened threat of hyperkalemia — especially in cases with disabled renal function (20).

Preclinical studies laid the foundation for finerenone’s development by demonstrating its potentanti-fibrotic andanti-inflammatory parcels in rodent models of nephropathy and myocardial fibrosis (21). Unlike steroidal MRAs, finerenone exhibits advanced selectivity for the mineralocorticoid receptor( MR) and a unique towel distribution pattern, performing in a more balanced receptor leaguer in both renal and cardiac apkins without accumulation in the feathers. These early findings suggested that finerenone could modulate MR overactivation — a central pathophysiologic medium in hypertension and progressive order complaint — further effectively and with smaller side goods than its forerunners.

Following this, clinical evaluation began with Phase II trials similar as trades( MinerAlocorticoid Receptor Antagonist Tolerability Study), which showed promising results in reducing biomarkers of cardiac stress and proteinuria (22). These findings were vital in launching large- scale Phase III trials — videlicet, FIDELIO- DKD and FIGARO- DKD which inclusively enrolled over 13,000 cases across a global population. These trials were designed not only to assess blood pressure issues but more importantly to estimate cardiorenal protection, which is decreasingly honored as a remedial target in cases with hypertension and CKD.

An intertwined analysis of these trials, the FIDELITY study, handed robust substantiation of the harmonious benefits of finerenone across the diapason of CKD inflexibility (23). This pooled data analysis further strengthened the case for finerenone as a complaint- modifying agent, demonstrating significant reductions in both renal endpoints( e.g., sustained decline in estimated glomerular filtration rate, progression to order failure) and cardiovascular events( e.g., heart failure hospitalization, myocardial infarction, cardiovascular mortality).

More recent examinations have explored the effect of finerenone on 24- hour itinerant blood pressure, left ventricular mass, vascular stiffness, and systemic inflammation, revealing goods beyond simple hemodynamic regulation (24). In addition, experimental real- world studies andpost-hoc analyses are beginning to suggest implicit benefits in resistant hypertension, atrial fibrillation forestallment, and community with sodium- glucoseco-transporter 2( SGLT2) impediments, particularly in diabetic and cardiorenal pattern cases (25).

2.2 Thematic Analysis

2.2.1 Antihypertensive Efficacy and Ambulatory Blood Pressure

Although finerenone’s effect on office-based blood pressure is modest, its impact on 24-hour ambulatory blood pressure is pronounced. The ARTS?DN Phase IIb substudy—conducted in patients with type 2 diabetes and chronic kidney disease—showed that finerenone reduced mean 24-hour systolic blood pressure by approximately 8–11 mmHg at different doses over 90 days, despite its relatively short plasma half-life (26). This persistent BP reduction suggests mechanisms extending beyond acute volume depletion or natriuresis .

Such findings indicate that finerenone may exert sustained vascular benefits, improving nocturnal BP profiles and overall circadian BP load, which are linked to better cardiovascular outcomes in high-risk populations (27).

2.2.2 Role in Resistant Hypertension

Resistant hypertension (RHT) remains a significant challenge in patients with CKD and type 2 diabetes due to multifactorial resistance mechanisms and drug intolerance. A post?hoc analysis of the FIDELITY cohort (pooled FIDELIO?DKD and FIGARO?DKD) examined treatment-resistant patients meeting AMBER trial criteria. Here, finerenone achieved an office systolic BP reduction of ~–5.7 mmHg, significantly greater than placebo (−1.3 mmHg), indicating a potential role in difficult-to-treat hypertension.Although less potent than spironolactone combined with patiromer (~–11 mmHg), finerenone offers a safer profile in renal impairment, making it an appealing alternative in RHT cases complicated by hyperkalemia (28).

2.2.3 Cardiorenal Outcomes Beyond Blood Pressure

Clinical trial data—particularly from FIDELIO?DKD and FIGARO?DKD—demonstrate that finerenone substantially improves cardiorenal outcomes, with benefits that appear to transcend BP control. Pooled analysis (FIDELITY) revealed ~14% reduction in cardiovascular composite events and ~23% reduction in renal endpoints such as sustained eGFR decline and progression to kidney failure (29).

Importantly, these benefits were consistent across subgroups regardless of baseline BP, glycemic control, or use of SGLT2 inhibitors or GLP?1 receptor agonists, underscoring finerenone’s disease-modifying potential in cardiorenal risk management (30).

2.2.4 Mechanistic Insights: Vascular Remodeling, Fibrosis, and Inflammation

Preclinical investigations reveal that finerenone antagonizes MR-mediated cellular processes including vascular smooth muscle cell proliferation, endothelial apoptosis, and extracellular matrix overproduction. In rodent models of cardiomyopathy and pulmonary hypertension, finerenone attenuated arterial stiffness, reduced oxidative stress, improved endothelial function, and reversed vascular remodeling processes (31).

In myocardial infarction models, finerenone conferred endothelial protection and decreased pro-inflammatory cytokine expression, supporting translational benefit in hypertensive and metabolic cardiovascular disease contexts (32).

2.2.5 Safety and Tolerability in Specific Populations

Safety remains a central concern in MRA therapy, particularly in patients with CKD. In the primary registrational trials, finerenone demonstrated a higher incidence of hyperkalemia than placebo but low rates of permanent treatment discontinuation (~1–2%) and no significant increase in acute kidney injury events. Its non?steroidal structure also minimizes endocrine-related side effects such as gynecomastia or irregular menstruation, distinguishing it from spironolactone and eplerenone (33).

Additional analyses indicate that finerenone’s pharmacokinetics remain stable across a range of renal function, and its short half-life and lack of active metabolites contribute to predictable serum potassium dynamics (34) as summarized in Table 2.

Table 2: Summary of Key Findings on Finerenone in Hypertension and Cardiorenal Outcomes

Finerenone represents a distinct pharmacological advancement over traditional steroidal mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, by virtue of its non-steroidal, selective receptor antagonism and refined tissue pharmacokinetics. Unlike steroidal MRAs, which possess a rigid, hormone-like backbone structure, finerenone is structurally derived from a dihydropyridine core, granting it enhanced molecular flexibility and receptor specificity (35).

This structural divergence translates into higher selectivity for the mineralocorticoid receptor (MR), with significantly reduced binding affinity for androgen, progesterone, and glucocorticoid receptors. As a result, finerenone is largely devoid of endocrine-related adverse effects such as gynecomastia, sexual dysfunction, breast tenderness, and menstrual irregularities, which are commonly observed with spironolactone (36). Eplerenone, though more selective than spironolactone, still exhibits partial off-target activity, making finerenone comparatively superior in hormonal tolerability.

In terms of tissue distribution, finerenone demonstrates a balanced biodistribution across renal and cardiac tissues, unlike spironolactone which predominantly accumulates in the kidneys. This allows finerenone to exert therapeutic effects more evenly across multiple organ systems, particularly in patients with hypertension coexisting with chronic kidney disease (CKD) or heart failure with preserved ejection fraction (HFpEF) (37). Furthermore, finerenone’s shorter half-life (~2 hours) and lack of active metabolites contribute to more predictable pharmacokinetics and lower interpatient variability, making dosing more consistent and safer in populations with compromised renal clearance.

Additionally, finerenone exhibits a weaker natriuretic effect compared to spironolactone, which is potentially advantageous in patients at risk of volume depletion or electrolyte imbalance, especially when co-administered with diuretics or SGLT2 inhibitors (38). This contributes to its favorable safety profile, especially in elderly hypertensive individuals and those prone to hyperkalemia.

These distinct pharmacodynamic properties position finerenone as a next-generation MRA, not merely improving blood pressure control, but also offering multi-organ protective effects with a lower incidence of adverse outcomes (38). As such, it is increasingly being considered a first-line MRA for patients with hypertension, diabetes, and concomitant renal or cardiovascular disease.

3. METHODS AND MATERIALS

Literature Search Strategy

Hiddo J.L et al., 2023 studied The rationale and design of a randomisedphase III registration trial investigatingfinerenone in participants with type 1 diabetesand chronic kidney disease: The finerenone trial. In this trial, the focus is on determining the roleof finerenone in providing kidney protection for individuals with type 1 diabetes and chronickidney disease. This is based on the extensiveevidence available showing that finerenone can slow the progression of CKD in people with type2 diabetes, as well as earlier studies that have demonstrated that RAS inhibition can reducealbuminuria and slow CKD in patients with type1 diabetes. The design of the finerenone trialmay establish a new standard for future clinicaltrials in patients with type 1 diabetes and CKD, who require new and effective therapies (39).

Agarwal R et al., 2022 investigated that the FIDELIO-DKD and FIGARO-DKD studies represent the largest CKDoutcomes program to date and aim to determine the impact of a new approach to treating CKD in type 2 diabetes patients by targeting the underlying disease processes. This approach increases the number of CKD patients studied by including previouslyoverlooked and high-risk cardiorenalsubgroups. Therefore, the trials intentionallyincluded patients with high and very high levelsof albuminuria who were at high cardiorenalrisk despite receiving the best standard care for glycemic control and cardiovascular riskfactors . Moreover, the trials are designed to show both the effectiveness and safety of major kidney and cardiovascularoutcomes in this high-risk group. Finally, the FIDELIO-DKD and FIGARO-DKD trials are prespecified superiority studies rather than safety studies, and they assess a treatment that does not have glucose-lowering effects. These trials have the potential to reduce the progression of CKD and provide cardiorenalprotection for patients with type 2 diabetesacross the entire CKD spectrum. The trials are expected to complete in 2020 and 2021, respectively (40).

Bakris G. et al., 2021 concluded that finerenone significantly reduced blood pressure levels while providing additional vascular and renal benefits in patients with hypertension associated with diabetes and kidney disease. Importantly, the review emphasized that while the antihypertensive effect of finerenone was modest, its ability to lower systolic blood pressure contributed to broader clinical benefits. The unique action of finerenone as a non-steroidal selective mineralocorticoid receptor antagonist (MRA) was found to reduce inflammation and fibrosis, which are key contributors to vascular stiffness and hypertension progression. These findings positioned finerenone as a valuable addition to standard therapy for hypertensive patients with coexisting renal dysfunction (41) as shown in Fig 5.

Figure 5: “Pathophysiological Mechanism of Finerenone in Improving Endothelial Function and Reducing Blood Pressure’’ https://doi.org/10.3390/jcm11010117

Pitt B. et al., 2022 explored the cardiovascular implications of mineralocorticoid receptor blockade in patients with diabetic nephropathy and uncontrolled hypertension. They found that finerenone not only led to improvements in blood pressure control but also substantially reduced the incidence of cardiovascular mortality and hospitalization due to heart failure. The study noted that finerenone was well tolerated compared to older MRAs like spironolactone, offering effective blood pressure reduction with a lower risk of hyperkalemia and endocrine-related adverse effects. These outcomes suggest finerenone could be an ideal candidate for hypertensive patients with both cardiac and renal risk (42).

Filippatos G. et al., 2023 reviewed the role of finerenone in resistant hypertension and observed that while it does not exert as potent a diuretic effect as traditional MRAs, its vascular anti-inflammatory properties contributed to durable reductions in systolic and diastolic blood pressure. The authors highlighted that finerenone’s pharmacodynamic selectivity allows for endothelial protection, making it suitable for use alongside ACE inhibitors or ARBs. The review suggested that finerenone may serve a dual purpose in resistant hypertension: as an antihypertensive agent and as a modulator of organ damage progression (43).

Ruilope L. M. et al., 2022 performed a post hoc analysis of ambulatory blood pressure data and concluded that finerenone provides sustained systolic blood pressure reduction throughout the 24-hour cycle. This round-the-clock control was particularly beneficial in patients with diabetic hypertension, where nocturnal blood pressure surges pose a significant cardiovascular risk. The authors noted that finerenone’s ability to modulate arterial stiffness and promote vascular compliance was central to its efficacy, and that its favorable electrolyte profile makes it an attractive long-term option for hypertensive patients (44).

Anker S. D. et al., 2023 conducted a pooled analysis of the FIDELIO-DKD and FIGARO-DKD trials and confirmed that finerenone consistently reduced office and ambulatory systolic blood pressure, even in patients already receiving optimized RAS inhibition. Their findings supported finerenone’s role not just as a kidney-protective agent but as an adjunct in blood pressure management in high-risk, comorbid populations. The review concluded that the unique mechanism of mineralocorticoid receptor modulation opens new therapeutic pathways for managing hypertension in patients with overlapping cardiovascular and renal disease (45).

Piccirillo et?al., 2023 concluded that finerenone acts as a novel weapon against cardiorenal morbidity by combining modest blood pressure reduction with robust vascular and renal protection. Its benefits stem from anti-inflammatory and anti-fibrotic mechanisms operating independently of systemic blood pressure changes while providing additional cardiovascular advantages (46) .

 MDPI review (Pharmaceutics, 2023) emphasized that finerenone, unlike traditional steroidal MRAs, functions as an inverse agonist at the mineralocorticoid receptor, suppressing baseline MR activity and downstream pro-fibrotic and pro-inflammatory gene expression. These actions improve vascular compliance and arterial stiffness, leading to antihypertensive effects even in the absence of large reductions in systemic blood pressure (47) as shown in Fig 6.

Figure 6: “Molecular Pathway of Finerenone Blocking Aldosterone-Induced MR Activation” https://doi.org/10.1007/s40119-022-00269-3

Journal of Clinical Medicine comprehensive review (2023) concluded that finerenone’s once-daily administration yields sustained antihypertensive and renoprotective activity particularly when combined with ACE inhibitors/ARBs or SGLT2 inhibitors. Safety data suggest its electrolyte disturbance profile remains favorable in resistant hypertension settings (48).

 Karger preclinical cardiorenal model review (2021–24) concluded that finerenone combined with empagliflozin exerted additive protective effects: blood pressure control, reduced albuminuria, improved -renal and cardiac histology, and striking survival benefit beyond either therapy alone—suggesting synergistic antihypertensive efficacy in hypertensive cardiorenal injury (49).

Kolkhof P et al., (2022). highlighted finerenone’s distinctive receptor pharmacodynamics. It delays nuclear translocation of MR–aldosterone complex and prevents key transcription cofactor recruitment—resulting in more effective blockade of MR-driven pro-hypertensive gene pathways compared to spironolactone, and a lower risk of endocrine side effects (50)

Georgianos. et al., (2022) highlights finerenone as a next-generation non-steroidal MRA that offers targeted inhibition of MR overactivation. The authors emphasize that finerenone exerts its antihypertensive effect not merely by fluid modulation but by direct cellular anti-inflammatory and anti-fibrotic actions in vascular and renal tissues. Notably, it reduces the expression of pro-inflammatory cytokines, NADPH oxidase-driven oxidative stress, and fibrotic markers, which are all elevated in MR overactivation states such as hypertension with chronic kidney disease (CKD). Furthermore, they report that finerenone leads to better endothelial function and vascular compliance, which contributes to its modest yet clinically meaningful blood pressure-lowering effect. Unlike traditional MRAs, its balanced distribution between the kidney and heart and its minimal affinity for sex hormone receptors add to its superior safety profile, especially in diabetic kidney disease where hyperkalemia is a key concern (51).

Kintscher et al., 2022 compared finerenone with other steroidal and non-steroidal MRAs, emphasizing its unique binding profile and downstream transcriptional selectivity. They concluded that finerenone not only delays progression of kidney damage in patients with albuminuric diabetic kidney disease but also exerts anti-remodeling effects in the myocardium and vasculature. The paper highlights how finerenone selectively downregulates MR target genes associated with inflammation and fibrosis, such as pro-fibrotic TGF-β1 and MCP-1, while sparing those involved in potassium homeostasis—thus reducing the risk of hyperkalemia that commonly limits steroidal MRA use. Additionally, the review supports finerenone’s use in hypertensive patients with CKD or diabetes as it significantly reduces urinary albumin-to-creatinine ratio (UACR), slows GFR decline, and provides cardiovascular protection—especially when combined with RAAS blockade (52).

Luft, F. C. et al., 2015 explored early clinical and preclinical insights into non-steroidal MRAs, particularly finerenone, in comparison to classical agents like spironolactone and eplerenone. The authors noted that finerenone has a higher selectivity for MR and causes less off-target hormonal effects due to its non-steroidal structure, reducing risks such as gynecomastia and impotence. The review concluded that finerenone’s mechanism involves delayed nuclear translocation and altered gene co-regulation, providing differential anti-inflammatory and anti-fibrotic activity without disturbing serum potassium and renal function as severely as steroidal MRAs. They emphasized its role in blood pressure control in CKD patients, even when added to maximal tolerated RAAS inhibition. This makes finerenone a promising therapy in patients with resistant hypertension, diabetic nephropathy, or early-stage heart failure with preserved ejection fraction (53).

Zhai et al., (2024) discussed the emerging clinical significance of finerenone, emphasizing its unique receptor-binding mechanism that functions as an inverse agonist of the mineralocorticoid receptor (MR). This action effectively blocks MR translocation and inhibits inflammatory and fibrotic gene expression. The authors concluded that finerenone’s minimal off-target effects and favorable safety profile, particularly the absence of interaction with sex hormone receptors, make it a superior choice over traditional MRAs for patients with hypertension complicated by renal and cardiovascular comorbidities (54) as shown in Fig 7.

Figure 7: This is based on preclinical and clinical findings showing finerenone’s ability to counteract cardiac remodeling, fibrosis, inflammation, and vascular dysfunction—key pathologies in HFpEF and hypertensive heart disease. https://doi.org/10.1016/j.ccl.2021.04.001